Alkermes (ALKS) Cash from Investing Activities (2010 - 2026)
Alkermes (ALKS) reported Cash from Investing Activities of -$2.1 billion for Q1 2026, down 22919.16% year-over-year from N/an in Q1 2025, and down 744.34% quarter-over-quarter from $322.3 million in Q4 2025.
Alkermes (ALKS) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has 17 years of Cash from Investing Activities data on file, last reported at -$2.1 billion in Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at -$2.1 billion, down 22919.16% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.8 billion (down 2776.24% YoY), and the FY2025 annual result was $295.5 million, up 365.48% from the prior year.
- Cash from Investing Activities declined to -$2.1 billion in Q1 2026 per ALKS's latest filing, from $322.3 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $322.3 million in Q4 2025 and troughed at -$2.1 billion in Q1 2026.
- A 5-year average of -$112.0 million and a median of -$13.9 million in 2024 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2022 and 2026: Cash from Investing Activities soared 3838.54% in 2022, then tumbled 22919.16% in 2026.
- A 5-year view of Cash from Investing Activities shows it stood at $27.7 million in 2022, then sank by 175.64% to -$21.0 million in 2023, then surged by 33.87% to -$13.9 million in 2024, then surged by 2423.21% to $322.3 million in 2025, then slumped by 744.34% to -$2.1 billion in 2026.
- Business Quant data shows ALKS's Cash from Investing Activities at -$2.1 billion in Q1 2026, $322.3 million in Q4 2025, and -$6.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 229.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | -87.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 743.70 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | -506.20 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | -60.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -2.08 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -15.45 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 25.99 Mn |
| 10 | Liquidia | 5.64 Bn | 5.42 Bn | 121.79 Mn | -2.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.08 Bn |
| Mar 31, 2026 | -2.08 Bn |
| Dec 31, 2025 | 322.35 Mn |
| Dec 31, 2025 | 322.35 Mn |
| Sep 30, 2025 | -6.74 Mn |
| Sep 30, 2025 | -6.74 Mn |
| Jun 30, 2025 | -29.21 Mn |
| Jun 30, 2025 | -29.21 Mn |
| Mar 31, 2025 | 9.10 Mn |
| Mar 31, 2025 | 9.10 Mn |
| Dec 31, 2024 | -13.88 Mn |
| Dec 31, 2024 | -13.88 Mn |
| Sep 30, 2024 | -109.33 Mn |
| Sep 30, 2024 | -109.33 Mn |
| Jun 30, 2024 | 51.85 Mn |
| Jun 30, 2024 | 51.85 Mn |
| Mar 31, 2024 | -39.95 Mn |
| Mar 31, 2024 | -39.95 Mn |
| Dec 31, 2023 | -20.98 Mn |
| Dec 31, 2023 | -20.98 Mn |